Shedding light on the link between a type of antibodies and miscarriage
Miscarriage affects an estimated 15% of pregnancies, but in about half of cases the cause is unclear. At Yale, reproductive immunologist Vikki Abrahams and reproductive biologist Mancy Tong are interested in shedding light on one of these causes.Source: YaleNews
We know the pain of stillbirth, and we're working to lower the numbers in the US
In October, the Stillbirth Health Improvement and Education (SHINE) for Autumn Act was introduced by Reps. Jaime Herrera Beutler, R-Wash., Lucille Roybal-Allard, D-Calif., Kathy Castor, D-Fla., and Markwayne Mullin, R-Okla. Passed in the House on Dec. 8, this bill has been introduced in the Senate by Cory Booker, D-N.J., and Marco Rubio, R-Fla. We commend the bipartisan advancement of this legislation to finally address the stillbirth crisis in our country.Source: USA Today
New research seeks to improve heart health for individuals with endometriosis
March is endometriosis awareness month, and researchers at The John B. Pierce Laboratory/Yale School of Medicine are working to improve public awareness and scientific understanding of the disorder.Source: The John B. Pierce Laboratory
WHRY Launches Studies on Endometrial Cancer, Addiction to Opioids, and Stroke
While continuing to focus on the impacts of COVID-19, the center has enlarged its research portfolio to include new projects on the prevention of endometrial cancer in a growing cohort of women at high risk, non-opioid pain management following a cesarean section for women with opioid use disorder who are in recovery, and sex differences in stroke.
Trastuzumab Duocarmazine Under Exploration in HER2+ Endocrine Cancer
Investigators are evaluating the safety and efficacy of the investigational antibody-drug conjugate vic-trastuzumab duocarmazine in patients with HER2-expressing recurrent, advanced, or metastatic endometrial cancer in the phase 2 SYD985.003 trial.Source: OncLive
Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.